GELS Key Statistics, Chart & Performance
The current stock price of GELS is 0.805 USD. In the past month the price decreased by -22.6%. In the past year, price decreased by -67.28%.
GELS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.1 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.51B | ||
| MRK | MERCK & CO. INC. | 12.04 | 263.24B | ||
| PFE | PFIZER INC | 7.81 | 142.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.26 | 110.36B | ||
| ZTS | ZOETIS INC | 19.94 | 55.71B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.49 | 22.51B | ||
| VTRS | VIATRIS INC | 5.38 | 14.44B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.71 | 11.31B | ||
| CORT | CORCEPT THERAPEUTICS INC | 79.77 | 7.38B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.50B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.61B |
Related stock screener links
About GELS
Company Profile
Gelteq Ltd. operates as a biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 7 full-time employees. The company went IPO on 2024-10-29. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
Company Info
GELTEQ LTD
Level 4, 100 Albert Road
Melbourne VICTORIA AU
Employees: 7
Phone: 61390873990
GELTEQ LTD / GELS FAQ
Can you describe the business of GELTEQ LTD?
Gelteq Ltd. operates as a biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 7 full-time employees. The company went IPO on 2024-10-29. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
What is the current price of GELS stock?
The current stock price of GELS is 0.805 USD. The price decreased by -4.69% in the last trading session.
What is the dividend status of GELTEQ LTD?
GELS does not pay a dividend.
What is the ChartMill technical and fundamental rating of GELS stock?
GELS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of GELS stock?
GELTEQ LTD (GELS) operates in the Health Care sector and the Pharmaceuticals industry.
Who owns GELTEQ LTD?
You can find the ownership structure of GELTEQ LTD (GELS) on the Ownership tab.
GELS Technical Analysis
GELS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GELS. GELS has a bad profitability rating. Also its financial health evaluation is rather negative.
GELS Financial Highlights
Over the last trailing twelve months GELS reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -87.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.94% | ||
| ROE | -42.05% | ||
| Debt/Equity | 0 |